Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

50%

2 trials in Phase 3/4

Results Transparency

0%

0 of 4 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01852149Not ApplicableCompleted

Mitralign Percutaneous Annuloplasty First in Man Study

Role: collaborator

NCT01113372Phase 4Completed

Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial

Role: lead

NCT00989066Completed

Brazil Xience V Everolimus-Eluting Coronary Stent System "Real-World" Outcomes Registry

Role: lead

NCT01368627Phase 4Completed

The E-SERIES Registry for Supralimus® Coronary Stent for the Treatment of Unselected Patients With Coronary Lesions

Role: collaborator

All 4 trials loaded